In the last decade, there has been

In the last decade, there has been remarkable success in applying targeted molecular therapies for the treatment of cancer. These approaches are typically based on modulating aberrant signal transduction pathways within the cancer cell. However, cancer remains one of the leading causes of morbidity and mortality worldwide with approximately 14 million new cases and 8.8 million cancer related deaths every year. Furthermore, benefits of these targeted therapies can often be short lived as tumor resistance is often observed. As such, new oncology treatments are needed to provide improved and more sustained benefit to patients.[1]Figure 1. Kiss of death: A cytotoxic T-cell (lower left) attacking a cancer cell (upper right). Immunofluorescence for actin (green), DAPI stained nuclei (blue), CellTracker Orange CMRA labeled T cells (red). Microscope: Zeiss LSM 880 with AiryScan, 63x/1.4 oil. Scale bar (white, lower right): 5µm.